Education
About Us
Working with TipRanks
Follow Us
Vaxcyte, Inc. (PCVX)
NASDAQ:PCVX
PCVX Stock Chart & Stats
$54.72
-$2.14(-2.45%)
At close: 4:00 PM EST
$54.72
-$2.14(-2.45%)
Day’s Range― - ―
52-Week Range$27.66 - $75.33
Previous CloseN/A
Volume105.48K
Average Volume (3M)1.26M
Market Cap
$7.88B
Enterprise Value$7.93B
Total Cash (Recent Filing)$1.56B
Total Debt (Recent Filing)$228.84M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
May 11, 2026EPS Estimate
-1.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.81
Shares Outstanding143,920,360
10 Day Avg. Volume1,317,364
30 Day Avg. Volume1,261,790
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio-9.38
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-10.14
Forecast
1Y Price Target
$105.14Price Target Upside92.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-7.07
Revenue Forecast (FY)$18.75M
Bulls Say, Bears Say
Bulls Say
Clinical Development And FundingOn-schedule adult enrollment, a completed infant trial enrollment, and a strong balance sheet support the ability to reach multiple high-impact clinical readouts and pursue regulatory filings.
Product DifferentiationVAX-31's broader serotype coverage and more precise antigen coupling position the vaccine to provide broader protection than existing pneumococcal vaccines, creating a clear commercial advantage.
Regulatory PathwayA pivotal OPUS head-to-head Phase 3 program designed to demonstrate non-inferiority against current standard vaccines establishes a clear regulatory and commercialization pathway if trial endpoints are achieved.
Bears Say
Clinical Efficacy RiskThere is a risk that VAX-31 may not generate adequate immune responses for some serotypes, which would weaken its differentiation and competitive position.
Financial PressureHigher projected operating expenses raise future funding needs and could moderate valuation upside if additional capital is required.
Statistical Trial HurdlesStrict statistical success requirements for the pivotal trials could be challenging to meet and could limit regulatory acceptance and market adoption if not achieved.
Vaxcyte News
PCVX FAQ
What was Vaxcyte, Inc.’s price range in the past 12 months?
Vaxcyte, Inc. lowest stock price was $27.66 and its highest was $75.33 in the past 12 months.
What is Vaxcyte, Inc.’s market cap?
Vaxcyte, Inc.’s market cap is $7.88B.
When is Vaxcyte, Inc.’s upcoming earnings report date?
Vaxcyte, Inc.’s upcoming earnings report date is May 11, 2026 which is in 48 days.
How were Vaxcyte, Inc.’s earnings last quarter?
Vaxcyte, Inc. released its earnings results on Feb 24, 2026. The company reported -$1.81 earnings per share for the quarter, missing the consensus estimate of -$1.53 by -$0.28.
Is Vaxcyte, Inc. overvalued?
According to Wall Street analysts Vaxcyte, Inc.’s price is currently Undervalued.
Does Vaxcyte, Inc. pay dividends?
Vaxcyte, Inc. does not currently pay dividends.
What is Vaxcyte, Inc.’s EPS estimate?
Vaxcyte, Inc.’s EPS estimate is -1.78.
How many shares outstanding does Vaxcyte, Inc. have?
Vaxcyte, Inc. has 143,920,360 shares outstanding.
What happened to Vaxcyte, Inc.’s price movement after its last earnings report?
Vaxcyte, Inc. reported an EPS of -$1.81 in its last earnings report, missing expectations of -$1.53. Following the earnings report the stock price went up 2.755%.
Which hedge fund is a major shareholder of Vaxcyte, Inc.?
Currently, no hedge funds are holding shares in PCVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vaxcyte Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$105.14 (92.14% Upside)
$105.14 (92.14% Upside)
Blogger Sentiment
Bullish
PCVX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $321.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-26.51%
12-Months-Change
Fundamentals
Return on Equity
-25.88%
Trailing 12-Months
Asset Growth
-13.79%
Trailing 12-Months
Company Description
Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
PCVX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a strongly positive operational and clinical momentum story: robust balance sheet extended by a ~$600M financing, completion of a commercial-scale manufacturing facility on time and on budget, initiation of three pivotal/Phase III adult OPUS trials with expected top-line readouts over the next 18 months, completed infant enrollment (900 infants), and resumption of the Group A Strep program. Offsetting risks are mostly predictable near-term impacts from materially higher R&D and manufacturing expenses in 2026, serotype-level regulatory uncertainties (and the idiosyncratic challenge of serotype 3), and a competitive landscape with other PCV developers. Overall, the highlights—particularly cash runway, manufacturing completion, and late-stage clinical progress—materially outweigh the lowlights, which are manageable programmatic and financial execution risks.View all PCVX earnings summariesPCVX Stock 12 Month Forecast
Average Price Target
$105.14
▲(92.14% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---